Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate

The pathogenic yeast, Candida albicans, is insensitive to the anti-mitotic drug, benomyl, and to the dihydrofolate reductase inhibitor, methotrexate. Genes responsible for the intrinsic drug resistance were sought by transforming Saccharomyces cerevisiae, a yeast sensitive to both drugs, with genomi...

Full description

Saved in:
Bibliographic Details
Published inMolecular & general genetics Vol. 227; no. 2; pp. 318 - 329
Main Authors Fling, M.E, Kopf, J, Tamarkin, A, Gorman, J.A, Smith, H.A, Koltin, Y
Format Journal Article
LanguageEnglish
Published Germany 01.06.1991
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:The pathogenic yeast, Candida albicans, is insensitive to the anti-mitotic drug, benomyl, and to the dihydrofolate reductase inhibitor, methotrexate. Genes responsible for the intrinsic drug resistance were sought by transforming Saccharomyces cerevisiae, a yeast sensitive to both drugs, with genomic C. albicans libraries and screening on benomyl or methotrexate. Restriction analysis of plasmids isolated from benomyl- and methotrexate-resistant colonies indicated that both phenotypes were encoded by the same DNA fragment. Sequence analysis showed that the fragments were nearly identical and contained a long open reading frame of 1694 bp (ORF1) and a small ORF of 446 bp (ORF2) within ORF1 on the opposite strand. By site-directed mutagenesis, it was shown that ORF1 encoded both phenotypes. The protein had no sequence similarity to any known proteins, including beta-tubulin, dihydrofolate reductase, and the P-glycoprotein of the multi-drug resistance family. The resistance gene was detected in several C. albicans strains and in C. stellatoidea by DNA hybridization and by the polymerase chain reaction.
ISSN:0026-8925
1432-1874
DOI:10.1007/BF00259685